Zacks Investment Research cut shares of Endo International (NASDAQ:ENDP) (TSE:ENL) from a buy rating to a hold rating in a report issued on Tuesday, September 18th.
According to Zacks, “Endo is in the process of redefining its business, given the persistent decline in the generic business and withdrawal of opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA’s request in June 2017. The focus now is on sterile injectables and Xiaflex. Sales of Xiaflex are being driven by increased demand in both Peyronie's disease and Dupuytren's contracture. Revenues from the sterile injectables business are being driven by the continued growth of Adrenalin. The business is poised to become Endo's core business. While the turnaround might take time, the company seems to be on the right track. Shares have outperformed the industry in the year so far. However, the generic business is expected to face further challenges. Competition is expected to intensify further in 2018.”
Several other analysts also recently issued reports on the stock. Goldman Sachs Group raised shares of Endo International from a sell rating to a neutral rating and upped their price target for the company from $14.00 to $15.00 in a report on Tuesday, September 11th. BidaskClub downgraded shares of Endo International from a strong-buy rating to a buy rating in a research note on Saturday, September 8th. ValuEngine downgraded shares of Endo International from a buy rating to a hold rating in a research note on Tuesday, September 4th. TheStreet raised shares of Endo International from a d rating to a c- rating in a research note on Monday, August 20th. Finally, Morgan Stanley upped their price objective on shares of Endo International from $7.00 to $17.00 and gave the company an equal weight rating in a research note on Friday, August 17th. Fifteen research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. Endo International currently has an average rating of Hold and an average target price of $14.55.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Wednesday, August 8th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.54 by $0.22. Endo International had a negative net margin of 34.72% and a positive return on equity of 237.45%. The company had revenue of $714.70 million for the quarter, compared to analyst estimates of $679.72 million. During the same period in the prior year, the business posted $0.93 earnings per share. The firm’s revenue for the quarter was down 18.4% compared to the same quarter last year. Equities research analysts anticipate that Endo International will post 2.6 EPS for the current year.
In related news, Director Roger H. Kimmel sold 26,074 shares of the firm’s stock in a transaction on Tuesday, August 14th. The shares were sold at an average price of $15.90, for a total transaction of $414,576.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.80% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in ENDP. Xact Kapitalforvaltning AB lifted its position in shares of Endo International by 44.5% in the 1st quarter. Xact Kapitalforvaltning AB now owns 29,215 shares of the company’s stock worth $174,000 after buying an additional 9,000 shares during the last quarter. Neuburgh Advisers LLC lifted its position in Endo International by 84.2% in the 1st quarter. Neuburgh Advisers LLC now owns 36,234 shares of the company’s stock valued at $215,000 after purchasing an additional 16,566 shares during the last quarter. Riverhead Capital Management LLC lifted its position in Endo International by 83.9% in the 1st quarter. Riverhead Capital Management LLC now owns 41,218 shares of the company’s stock valued at $245,000 after purchasing an additional 18,800 shares during the last quarter. United Services Automobile Association lifted its position in Endo International by 16.7% in the 2nd quarter. United Services Automobile Association now owns 41,508 shares of the company’s stock valued at $391,000 after purchasing an additional 5,933 shares during the last quarter. Finally, Tyers Asset Management LLC lifted its position in Endo International by 84.2% in the 1st quarter. Tyers Asset Management LLC now owns 46,116 shares of the company’s stock valued at $274,000 after purchasing an additional 21,084 shares during the last quarter. 98.43% of the stock is owned by institutional investors and hedge funds.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Recommended Story: How does inflation affect different investments?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.